EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea

Han-Sang Baek, Jeonghoon Ha iD, Seunggyun Ha, Ja Seong Bae, Chan Kwon Jung iD, Dong-Jun Lim iD

Current Oncology · 2023

DOI: 10.3390/curroncol30030229 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, 2023. Verfasst von Han-Sang Baek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of…. Hauptthemen laut MEDLINE: Adenocarcinoma, Thyroid Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, selpercatinib, a highly selective inhibitor of RET receptor tyrosine kinase, has been used for RET-altered thyroid cancer. We present four cases of patients with advanced thyroid cancer who were treated with selpercatinib. The first patient was a 63-year-old male with advanced medullary thyroid cancer (MTC) treated with vandetanib. Six months ago, he had an intracranial hemorrhage and swallowing difficulty. He started selpercatinib with percutaneous endoscopic gastrostomy (PEG). For 11 months, a partial response (PR) was observed stably with PEG administration without any more cardiovascular events. The second patient was a 67-year-old female with advanced MTC treated with vandetatib. After selpercatinib treatment, a PR was observed for most metastatic sites, including choroidal metastasis. The third patient was a 32-year-old female with advanced papillary thyroid cancer (PTC) without history of systematic treatment. For six months, a PR was observed at her metastatic site with manageable adverse events. The last patient was a 59-year-old female with advanced PTC treated with lenvatinib. She suffered from a panic disorder and pleural pain due to metastasis during lenvatinib treatment. After selpercatinib treatment, her pain and panic symptoms were improved. Facing varying clinical obstacles of the real world, selpercatinib safely proved remarkable therapeutic efficacy regardless of previous treatment or metastatic site.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaThyroid NeoplasmsAntineoplastic AgentsAdultMaleRepublic of KoreaFemaleHumansProtein Kinase InhibitorsProto-Oncogene Proteins c-retAgedMiddle AgedPhenylurea CompoundsQuinolinesPyrazolesPyridinesCarcinoma, Neuroendocrine

Stichwörter der Autor:innen

RET alterationgastrostomylenvatinibmedullarypapillaryselpercatinibthyroid cancer

Substanzen

Protein Kinase InhibitorsProto-Oncogene Proteins c-retAntineoplastic AgentslenvatinibPhenylurea CompoundsQuinolinesselpercatinibPyrazolesPyridinesRET protein, human

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.
  • Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.
  • Department of Surgery, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.
  • Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.

ORCID-Profile: Jeonghoon Ha, Chan Kwon Jung, Dong-Jun Lim

Zitieren

APA

Baek, H. S., Ha, J., Ha, S., Bae, J. S., Jung, C. K., & Lim, D. J. (2023). Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea. Current Oncology. https://doi.org/10.3390/curroncol30030229

Vancouver

Baek HS, Ha J, Ha S, Bae JS, Jung CK, Lim DJ. Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea. Current Oncology. 2023. doi:10.3390/curroncol30030229

BibTeX
@article{Baek2023,
  author = {Baek, Han-Sang and Ha, Jeonghoon and Ha, Seunggyun and Bae, Ja Seong and Jung, Chan Kwon and Lim, Dong-Jun},
  title = {Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30030229}
}
Kostenlos starten →